Understanding muscle wasting in ICU patients
Skeletal Muscle Wasting in ICU Patients
This study looks at how muscle loss happens in critically ill patients in the ICU to see if a special water can help understand and improve their recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | Hasselt University Academic / other |
| Locations | 1 site (Hasselt, Limburg) |
| Trial ID | NCT06234826 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on the rapid muscle wasting that occurs in critically ill patients, which negatively affects their recovery and long-term outcomes. It aims to investigate altered protein metabolism and muscle protein synthesis (MPS) rates during critical illness using oral deuterated water (2H2O) dosing. This method allows for the assessment of MPS over extended periods, providing insights that could inform future interventions to mitigate muscle loss in ICU settings. The study will involve patients who are expected to stay in the ICU for more than seven days and have specific medical conditions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who are admitted to the ICU and expected to stay for more than seven days.
Not a fit: Patients with spinal cord injuries, chronic corticosteroid use, or significant organ failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for preventing muscle wasting in critically ill patients, enhancing their recovery and quality of life.
How similar studies have performed: While few studies have explored muscle protein synthesis in ICU patients, this approach using oral deuterated water is relatively novel and has not been widely tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * age \>18y * admitted to ICU * enteral nutrition line in situ * arterial line (any location) in situ * expected stay ICU \>7d Exclusion Criteria: * spinal cord injury * chronic use of corticosteroids before hospital admission * Contraindication to enteral infusion (e.g. due to GI-tract perforation) * Kidney or liver failure * therapeutic anti coagulation
Where this trial is running
Hasselt, Limburg
- Jessa Hospital — Hasselt, Limburg, Belgium (Recruiting)
Study contacts
- Principal investigator: Frank Vandenabeele, Prof. — Hasselt University
- Study coordinator: Michelle Weijzen, Dr.
- Email: michelle.weijzen@uhasselt.be
- Phone: 003211268706
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.